AAML1921; Bosutinib for Chronic Myeloid Leukemia



Subscribe to be notified of changes or updates to this page.

6 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called bosutinib. The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).

Eligibility & Criteria

IRB #:
Official Title:
AAML1921, A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 17 Years
Study Categories:

Visit Criteria

Participation will last for up to 10 years. Subjects will receive Bosutinib once daily. Study visits include the following assessments: blood draws, bone marrow aspirate (if procedure is performed as part of regular clinical care), collection of extra blood and tissue for future research, and the completion of diaries and questionnaires.